LAUSR

Three topics on endocrine therapy of preand postmenopausal patients with hormone-receptor positive breast cancer were discussed in detail: ovarian function suppression (OFS), aromoatase inhibitors (AI) and extended endocrine therapy. The panel acknowledged that patients below 35 years of age, premenopausal after chemotherapy or with 4 or more involved lymph nodes should receive OFS. AI treatment should be given to postmenopausal women especially with grade 3 or node-positive tumors, but reverse-switch of an AI to tamoxifen after 2 years was not supported by the panel. Preand postmenopausal patients at higher risk can be offered extended endocrine therapy. So regarding all three topics, risk is the main driver of the decision of whether to use OFS, AI and/or extended endocrine therapy. But – in my opinion – the most important question regarding endocrine therapy was not addressed: